Minnesota-based ANI Pharmaceuticals, which specializes in generics manufacture, and is now branching into rare diseases treatment, has appointed Meredith Cook as general counsel.

Cook, who has more than 20 years of experience in M&A, joins ANI eight months after the company completed its $210 million purchase of Novitium Pharma, a maker of niche generic treatments.